

01/04/01

PTO/SB/05 (2/98)

Approved for use through 09/30/2000, OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Utility  
Patent Application  
Transmittal

(Only for new nonprovisional applications under 37 C.F.R. §1.53(b))

Attorney Docket No.

PC9978A

First Named Inventor or Application Identifier

FUMITAKA ITO

Title

BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS

Express Mail Label No.

EL 162 814 379 US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)

2.  Specification [Total Pages 86] [ ]

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference in Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.  Drawing(s) (35 U.S.C. 11.3) [Total sheets ] [ ]

4.  Oath or Declaration [Total pages ] [ ]

- a.  Newly executed (original or copy)
- b.  Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 17 completed)  
(Note Box 5 below)

5.  Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO:  
Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

6.  Microfiche Computer Program (Appendix)

7.  Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

- a.  Computer Readable Copy
- b.  Paper Copy (identical to computer copy)
- c.  Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8.  Assignment Paper (cover sheet & document(s))

9.  37 C.F.R. §3.73(b) Statement  Power of Attorney  
(when there is an assignee)

10.  English Translation Document (if applicable)

11.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations

12.  Preliminary Amendment

13.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)

14.  \*Small Entity  Statement filed in prior application, Statements(s)  
(PTO/SB/09-12)  Status still proper and desired

15.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)

16.  Other: Priority Claim

This application claims the benefit of  
provisional application Ser. No. 60/174,542,  
filed January 5, 2000

\*NOTE FOR ITEMS 1, 6-14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

 Continuation  Divisional Continuation-in-part (CIP)

of prior application No: /

Prior application information: Examiner \_\_\_\_\_

Group/Art Unit: \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

(Insert Customer No. or Attach bar code label here)

 Correspondence address below

Name Paul H. Ginsburg

Address Pfizer Inc

Address 235 East 42nd Street, 20th Floor

City New York

State

New York

Zip Code

10017-5755

Country United States Of America

Telephone

(212)573-2369

Fax

(212)573-1939

NAME (Print/type) ROY F. WALDRON

Registration No. (Attorney/Agent)

42,208

Signature

Date

01/03/2001

EXPRESS MAIL NO. EL 162 814 379 US

01/03/2001  
0903 U.S. PTO  
09/03/2001  
09/03/2001

# FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/08-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$ 710.00)

## METHOD OF PAYMENT (check one)

1.  The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name PFIZER INC

Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17.  Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2.  Payment Enclosed:

Check  Money Order  Other

## FEE CALCULATION (continued)

Large Entity		Small Entity		Fee Description	Fee Paid		
Fee Code	Fee (\$)	Fee Code	Fee (\$)				
101	710	201	355	Utility filing fee	710.00		
106	320	206	160	Design filing fee			
107	490	207	245	Plant filing fee			
108	710	208	355	Reissue filing fee			
114	150	214	75	Provisional filing fee			
<b>SUBTOTAL (1) (\$)</b>		710.00					
<b>2. EXTRA CLAIM FEES</b>							
Extra Fee from Claims below							
Total Claims	10	-20% =	0	Fee Paid			
			0	X			
			18	=	0.00		
Independent Claims	1	- 3% =	0				
			0	X			
			80	=	0.00		
Multiple Dependent			270	=	0.00		
** or number previously paid, if greater; For Reissues, see below							
<b>Large Entity</b> <b>Small Entity</b>							
Fee Code (\$)		Fee Code (\$)		Fee Description			
103	18	203	9	Claims in excess of 20			
102	80	202	40	Independent claims in excess of 3			
104	270	204	135	Multiple dependent claim, if not paid			
109	80	209	40	**Reissue independent claims over original patent			
110	18	210	9	**Reissue claims in excess of 20 and over original patent			
<b>SUBTOTAL (2) (\$)</b>		0.00		<b>SUBTOTAL (3) (\$)</b>			

\*Reduced by Basic Filing Fee Paid

0.00

Complete (if Applicable)

Reg. Number 42,208

Deposit Account User ID 16-1445 PFIZER INC

## SUBMITTED BY

Type or Printed Name ROY F. WALDRON

Signature 

Date 01/03/2001

EXPRESS MAIL NO. EC 162814 379 45